Literature DB >> 18820

Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.

P J Tutschka, G W Santon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 18820     DOI： 10.1097/00007890-197707000-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  8 in total

1.  Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome.

Authors:  S Kanaji; S A Fahs; J Ware; R R Montgomery; Q Shi
Journal:  J Thromb Haemost       Date:  2014-08-26       Impact factor: 5.824

Review 2.  Preparation for bone marrow transplantation.

Authors:  R Parkman
Journal:  Springer Semin Immunopathol       Date:  1984

Review 3.  Displacement bone marrow transplantation for some inborn errors.

Authors:  J R Hobbs
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model.

Authors:  Naoya Uchida; Tina Nassehi; Claire M Drysdale; Jackson Gamer; Morgan Yapundich; Aylin C Bonifacino; Allen E Krouse; Nathaniel Linde; Matthew M Hsieh; Robert E Donahue; Cynthia E Dunbar; Leslie S Kean; John F Tisdale
Journal:  Mol Ther       Date:  2019-06-05       Impact factor: 11.454

5.  Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation.

Authors:  Shuichi Ashizuka; William H Peranteau; Satoshi Hayashi; Alan W Flake
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

6.  Immunomagnetic T-lymphocyte depletion (ITLD) of rat bone marrow using OX-19 monoclonal antibody.

Authors:  A L Hoffman; L Makowka; D V Cramer; X Cai; A Pascualone; B F Banner; D G Sheahan; P Rettinger; T E Starzl
Journal:  J Invest Surg       Date:  1989       Impact factor: 2.533

7.  Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

Authors:  I Boland; G Vassal; J Morizet; M J Terrier-Lacombe; D Valteau-Couanet; C Kalifa; O Hartmann; A Gouyette
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 8.  Immunoresponse to Gene-Modified Hematopoietic Stem Cells.

Authors:  Claire M Drysdale; John F Tisdale; Naoya Uchida
Journal:  Mol Ther Methods Clin Dev       Date:  2019-10-31       Impact factor: 6.698
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.